^
    11ms
    A Phase I/II study to evaluate the safety and efficacy of HZ-A-018 in relapsed/refractory primary or secondary central nervous system lymphoma(HZ-A-018-102) (ChiCTR2400091821)
    P1/2, N=101, Recruiting, Beijing TianTan Hospital,Captial Medical University; Hangzhou Healzen Therapeutics Co., Ltd.
    New P1/2 trial
    |
    IL6 (Interleukin 6) • IL10 (Interleukin 10)
    |
    HZ-A-018 • methotrexate IV
    over2years
    HZ-A-018, a novel inhibitor of Bruton tyrosine kinase, exerts anti-cancer activity and sensitizes 5-FU in gastric cancer cells. (PubMed, Front Pharmacol)
    Mechanismly, the combination of HZ-A-018 and 5-FU remarkably reduced the expression of RRM2, which played an essential role in proliferation and drug sensitivity in gastric cancer cells. In summary, our work demonstrated the stronger anti-cancer activity of HZ-A-018 than ACP-196 in gastric cancer cells, and revealed synergistic effects of HZ-A-018 and 5-FU combination probably through the inhibition of RRM2 via AKT/S6 pathway, thereby providing a promising therapeutic strategy in gastric cancer.
    Journal
    |
    BTK (Bruton Tyrosine Kinase) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
    |
    5-fluorouracil • Calquence (acalabrutinib) • HZ-A-018